Core B, the Neuroscience Core, is designed to facilitate the research conducted in each of the Projects of this Program Project grant by providing assistance and support for a number of 'core' activities that are common to Projects 1-4. Since all 4 Projects will require antibodies as essential tools for the proposed studies, a major activity will be the generation, characterization and provision of antibody probes to all investigators in this Program Project. A second core activity which is also essential to the success of Projects 1-4 is the provision of all reagents for the precise measurements of Abeta/1-40 and Abeta/1-42 in a sandwich ELISA. Since Projects 1-3 will use pure NT2N neurons for almost of the proposed studies, the Neuroscience Core will generate greater than 99% pure NT2N neurons in large quantities to supplement those generated by the individual labs. Core B will provide reagents and assistance for the use of Semliki Forest virus (SFV) vectors, and will also develop bicistronic SFV vectors for the expression of 2 different transgenes in NT2N cells. Finally, Core B will develop lentiviral vectors for stable and long-term expression of transgenes in post-mitotic NT2N neurons and in brains of experimental animals. In summary, by providing for several essential scientific needs of all of the Projects in this Program Project, the Neuroscience Core will play a vital role in contributing to the successful accomplishment of the research goals of this Program Project.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG011542-08
Application #
6340630
Study Section
Project Start
2000-09-01
Project End
2001-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
2000
Total Cost
$240,592
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Brunden, Kurt R; Ballatore, Carlo; Lee, Virginia M-Y et al. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-6
Hurtado, David E; Molina-Porcel, Laura; Carroll, Jenna C et al. (2012) Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease. J Neurosci 32:7392-402
Hurtado, David E; Molina-Porcel, Laura; Iba, Michiyo et al. (2010) A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 177:1977-88
Xu, Shaohua; Brunden, Kurt R; Trojanowski, John Q et al. (2010) Characterization of tau fibrillization in vitro. Alzheimers Dement 6:110-7
Brunden, Kurt R; Ballatore, Carlo; Crowe, Alex et al. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223:304-10
Crowe, Alex; Huang, Wenwei; Ballatore, Carlo et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-45
Chen, Xiao-Han; Johnson, Victoria E; Uryu, Kunihiro et al. (2009) A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol 19:214-23
Brunden, Kurt R; Trojanowski, John Q; Lee, Virginia M-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-93
Shineman, Diana W; Dain, Aleksandra S; Kim, Minkyu L et al. (2009) Constitutively active Akt inhibits trafficking of amyloid precursor protein and amyloid precursor protein metabolites through feedback inhibition of phosphoinositide 3-kinase. Biochemistry 48:3787-94
Kim, Minkyu L; Zhang, Bin; Mills, Ian P et al. (2008) Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J Neurosci 28:12052-61

Showing the most recent 10 out of 94 publications